How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/olmesartan-amlodipine-hydrochlorothiazide-if-necessary.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

olmesartan/amlodipine + hydrochlorothiazide, if necessary. — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

olmesartan/amlodipine + hydrochlorothiazide, if necessary. (olmesartan/amlodipine + hydrochlorothiazide, if necessary.) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antihypertensive combination (ARB + calcium channel blocker + thiazide diuretic). Area: Cardiov

marketed Antihypertensive combination (ARB + calcium channel blocker + thiazide diuretic) Angiotensin II type 1 receptor (AT1R), L-type calcium channels, sodium-chloride cotransporter (NCC) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

olmesartan/amlodipine + hydrochlorothiazide, if necessary. (olmesartan/amlodipine + hydrochlorothiazide, if necessary.) — Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company. This combination blocks angiotensin II receptors, inhibits calcium channels, and reduces sodium reabsorption in the kidney to lower blood pressure through multiple complementary pathways.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
olmesartan/amlodipine + hydrochlorothiazide, if necessary. TARGET	olmesartan/amlodipine + hydrochlorothiazide, if necessary.	Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company	marketed	Antihypertensive combination (ARB + calcium channel blocker + thiazide diuretic)	Angiotensin II type 1 receptor (AT1R), L-type calcium channels, sodium-chloride cotransporter (NCC)
Losartan and amlodipine and hydrochlorothiazide	Losartan and amlodipine and hydrochlorothiazide	Hotel Dieu de France Hospital	marketed	Antihypertensive combination (ARB + calcium channel blocker + thiazide diuretic)	Angiotensin II type 1 receptor (AT1R), L-type calcium channels, sodium-chloride cotransporter
irbesartan, amlodipine and hydrochlorothiazide	irbesartan, amlodipine and hydrochlorothiazide	Assistance Publique - Hôpitaux de Paris	marketed	Antihypertensive combination (ARB + calcium channel blocker + thiazide diuretic)	Angiotensin II type 1 receptor (AT1R), L-type calcium channels, sodium-chloride cotransporter

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antihypertensive combination (ARB + calcium channel blocker + thiazide diuretic) class)

Assistance Publique - Hôpitaux de Paris · 1 drug in this class
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company · 1 drug in this class
Hotel Dieu de France Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). olmesartan/amlodipine + hydrochlorothiazide, if necessary. — Competitive Intelligence Brief. https://druglandscape.com/ci/olmesartan-amlodipine-hydrochlorothiazide-if-necessary. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab